Radiation therapy of primary extranodal Non-Hodgkin's lymphoma of head and neck. Results of a prospective multicenter study
Creators
- 1. Strahlenklinik, Universitaetsklinikum Essen (Germany)
Description
Between January 1986 and August 1993, 63 patients with primary extranodal Non-Hodgkin lymphoma of head and neck region, stages IE and IIE were treated with radiotherapy. The histological classification followed the Kiel classification, staging the Ann Arbor classification. Patient characteristics: 33 Male, 30 female; age 18 to 84 years; tumor localisation: Tonsils 26, nasopharynx 7, oropharynx 8, paranasal sinus 11, salivary glands 7, floor of mouth/gingiva 3, larynx 1. Mean follow-up is 74 months. Low-grade lymphoma in stages I and II CS were treated with definitive radiation therapy according to the concepts of epithelial tumors of the same localisation (target volume and technique).The adjuvant dose was 30 Gy and in the tumor volume 40 Gy, 2 Gy daily. 28 patients were registered, 18 in stage I and 10 in stage II. High-grade lymphoma were treated with definitive radiation therapy according to the concepts of epithelial tumors of the same localisation, too. The dose was 40 respectively 50 Gy, followed by 4 course of adjuvant chemotherapy with CHOP. Thirty-five patients were enrolled, of whom only 10 received chemotherapy. The overall 5-year survical rates were for low-grade 67% and for high grade lymphoma 88%. The corresponding relapse-free survival rates were 54/68%, respectively. Only 1 patient failed within the irradiated target volume. Recurrences occurred at sites distant to the irradiated volume in nodal and extranodal regions. Prognosis was influenced by histologic grade. Significant trends were not observed for other potential pretreatment parameters (age, stage, localisation, bulk). (orig./MG)
Abstract (German)
Von Januar 1986 bis August 1993 wurden 63 Patienten mit primaer extranodalen Non-Hodgkin-Lymphomen der Kopf-Hals-Region in den Stadien CS IE und IIE (Ann Arbor) behandelt. Patientencharakteristika: 33 maennlich, 30 weiblich; Alter 18 bis 84 Jahre. Primaermanifestationen: Tonsille 26, Nasopharynx 7, Oropharynx 8, Nasennebenhoehlen 11, Speicheldruesen 7, Mundboden/Gingiva 3, Kehlkopf 1. Die mediane Nachbeobachtungszeit betraegt 74 Monate. Die niedrigmalignen Lymphome der Stadien IE und IIE erhielten eine definitive Strahlenbehandlung in Anlehnung an das Zielvolumenkonzept und die Bestrahlungstechnik der entsprechenden Karzinome. Die in konventioneller Fraktionierung applizierte Dosis war adjuvant 30 Gy und im Bereich des Tumors 40 Gy. 28 Patienten wurden eingebracht, davon 18 im Stadium I und zehn im Stadium II. Die hochmalignen Lymphome erhielten eine gleichartige Strahlenbehandlung wie die niedrigmalignen mit Gesamtdosen von 40 bzw. 50 Gy. Im Anschluss daran waren vier Kurse einer adjuvanten Chemotherapie mit CHOP vorgesehen. 35 Patienten wurden eingebracht, davon erhielten lediglich zehn Patienten die Chemotherapie. Die Fuenf-Jahres-Ueberlebensrate betrug 54% bzw. 68%. Die 24 beoabachteten Rezidive (38%) traten simultan oder isoliert extranodal und nodal ausserhalb der Bestrahlungsfelder auf, nur ein Rezidiv lag im Zielvolumen. In einer univariaten Analyse erwies sich einzig der Malignitaetsgrad als relevanter Faktor fuer das Gesamtueberleben. (orig./MG)Additional details
Additional titles
- Original title (German)
- Strahlentherapie primaer extranodaler Non-Hodgkin-Lymphome der Kopf-Hals-Region. Ergebnisse einer prospektiven multizentrischen Studie
Publishing Information
- Journal Title
- Strahlentherapie und Onkologie
- Journal Volume
- 172
- Journal Issue
- 7
- Journal Page Range
- p. 356-366.
- ISSN
- 0179-7158
- CODEN
- STONE4
INIS
- Country of Publication
- Germany
- Country of Input or Organization
- Germany
- INIS RN
- 27068280
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- CHEMOTHERAPY; COMBINED THERAPY; EFFICIENCY; FRACTIONATED IRRADIATION; HEAD; LYMPHOMAS; NECK; PATIENTS; RADIOTHERAPY; SURVIVAL CURVES; SURVIVAL TIME
- Descriptors DEC
- ANIMALS; BODY; BODY AREAS; DISEASES; IMMUNE SYSTEM DISEASES; IRRADIATION; MAMMALS; MAN; MEDICINE; NEOPLASMS; PRIMATES; THERAPY; VERTEBRATES